Barron Matthew
Known title: SVP, Gen Counsel & SecretaryCIK: 0001878541
Associated companies
Transaction History
| SLVM | ▼ Sell | Tax Withholding | 3,479 | $161K | 3/1/2026 | View on chart |
| SLVM | ▲ Buy | Grant | 7,854 | $0 | 3/1/2026 | View on chart |
| SLVM | ▲ Buy | Grant | 8,868 | $0 | 3/1/2026 | View on chart |
| SLVM | ▼ Sell | Tax Withholding | 5,480 | $390K | 3/1/2025 | View on chart |
| SLVM | ▲ Buy | Grant | 10,580 | $0 | 3/1/2025 | View on chart |
| SLVM | ▲ Buy | Grant | 5,486 | $0 | 3/1/2025 | View on chart |
| SLVM | ▲ Buy | Grant | 7,109 | $0 | 3/1/2024 | View on chart |
| SLVM | ▼ Sell | Tax Withholding | 1,628 | $98K | 3/1/2024 | View on chart |
| SLVM | ▼ Sell | Tax Withholding | 1,132 | $56K | 3/1/2023 | View on chart |
| SLVM | ▲ Buy | Grant | 5,508 | $0 | 3/1/2023 | View on chart |
| SLVM | ▼ Sell | Tax Withholding | 540 | $21K | 8/1/2022 | View on chart |
| SLVM | ▼ Sell | Tax Withholding | 704 | $25K | 3/1/2022 | View on chart |
| SLVM | ▲ Buy | Grant | 5,044 | $0 | 2/21/2022 | View on chart |
| SLVM | ▲ Buy | Grant | 2,216 | $0 | 10/15/2021 | View on chart |
| SLVM | ▲ Buy | Grant | 8,737 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sylvamo Price Targets Lowered by BofA and Truist
Bank of America and Truist Securities recently lowered their price targets for Sylvamo, citing updated outlooks. While BofA maintains a Neutral rating with a $42 target, Truist keeps a Buy rating but reduced its target to $40. These adjustments place the new targets below the current average analyst estimate of $50.40, reflecting a more cautious view on the company's near-term valuation.
Sylvamo Price Targets Lowered by BofA and Truist. Bank of America and Truist Securities recently lowered their price targets for Sylvamo, citing updated outlooks. While BofA maintains a Neutral rating with a $42 target, Truist keeps a Buy rating but reduced its target to $40. These adjustments place the new targets below the current average analyst estimate of $50.40, reflecting a more cautious view on the company's near-term valuation.